These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15553667)

  • 61. Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study.
    Burkholz SR; Herst CV; Carback RT; Harris PE; Rubsamen RM
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992227
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Trial watch: Peptide vaccines in cancer therapy.
    Vacchelli E; Martins I; Eggermont A; Fridman WH; Galon J; Sautès-Fridman C; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2012 Dec; 1(9):1557-1576. PubMed ID: 23264902
    [TBL] [Abstract][Full Text] [Related]  

  • 63. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
    Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
    Tsuruma T; Hata F; Torigoe T; Furuhata T; Idenoue S; Kurotaki T; Yamamoto M; Yagihashi A; Ohmura T; Yamaguchi K; Katsuramaki T; Yasoshima T; Sasaki K; Mizushima Y; Minamida H; Kimura H; Akiyama M; Hirohashi Y; Asanuma H; Tamura Y; Shimozawa K; Sato N; Hirata K
    J Transl Med; 2004 Jun; 2(1):19. PubMed ID: 15193151
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
    Honma I; Kitamura H; Torigoe T; Takahashi A; Tanaka T; Sato E; Hirohashi Y; Masumori N; Tsukamoto T; Sato N
    Cancer Immunol Immunother; 2009 Nov; 58(11):1801-7. PubMed ID: 19294381
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].
    Tsuruma T; Torigoe T; Hata F; Furuhata T; Sato N; Hirata K
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1634-6. PubMed ID: 15553667
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Survivin--a universal tumor antigen.
    Andersen MH; thor SP
    Histol Histopathol; 2002 Apr; 17(2):669-75. PubMed ID: 11962766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.